Cargando…

Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?

BACKGROUND: Numerous studies have reported myocarditis resulting from messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination. However, to date, there have been no reports highlighting the safety of mRNA COVID-19 vaccines in children and adults with a prior history of myocarditis, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahid, Rida, Tang, W.H. Wilson, Klein, Allan L., Kwon, Deborah, Amdani, Shahnawaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277999/
https://www.ncbi.nlm.nih.gov/pubmed/35842104
http://dx.doi.org/10.1016/j.cardfail.2022.06.011
_version_ 1784746106340507648
author Shahid, Rida
Tang, W.H. Wilson
Klein, Allan L.
Kwon, Deborah
Amdani, Shahnawaz
author_facet Shahid, Rida
Tang, W.H. Wilson
Klein, Allan L.
Kwon, Deborah
Amdani, Shahnawaz
author_sort Shahid, Rida
collection PubMed
description BACKGROUND: Numerous studies have reported myocarditis resulting from messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination. However, to date, there have been no reports highlighting the safety of mRNA COVID-19 vaccines in children and adults with a prior history of myocarditis, which was the intent of this study. METHODS AND RESULTS: Children and adults cared for at the Cleveland Clinic were identified through the electronic health records, who had a history of myocarditis before the COVID-19 pandemic and had subsequently received at least 2 doses of the mRNA COVID-19 vaccines (n = 34). Only 1 patient in this series had recurrence of myocarditis confirmed by cardiac magnetic resonance imaging after receiving the second dose. He was a White man who had his first episode of myocarditis at age 20 and was 27 years of age at the time of recurrence. He was hospitalized for 2 days with no need for cardiac support or reported arrhythmias and was stable at outpatient follow-up. CONCLUSIONS: In patients with an old history of non–COVID-19 myocarditis, the risk of recurrent myocarditis after receipt of mRNA COVID-19 vaccination is low, and when it occurs it seems to be self-limiting. Our study will be valuable to clinicians while discussing the risk–benefit ratio of vaccinations in patients with a prior history of myocarditis.
format Online
Article
Text
id pubmed-9277999
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92779992022-07-14 Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis? Shahid, Rida Tang, W.H. Wilson Klein, Allan L. Kwon, Deborah Amdani, Shahnawaz J Card Fail Brief Report BACKGROUND: Numerous studies have reported myocarditis resulting from messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination. However, to date, there have been no reports highlighting the safety of mRNA COVID-19 vaccines in children and adults with a prior history of myocarditis, which was the intent of this study. METHODS AND RESULTS: Children and adults cared for at the Cleveland Clinic were identified through the electronic health records, who had a history of myocarditis before the COVID-19 pandemic and had subsequently received at least 2 doses of the mRNA COVID-19 vaccines (n = 34). Only 1 patient in this series had recurrence of myocarditis confirmed by cardiac magnetic resonance imaging after receiving the second dose. He was a White man who had his first episode of myocarditis at age 20 and was 27 years of age at the time of recurrence. He was hospitalized for 2 days with no need for cardiac support or reported arrhythmias and was stable at outpatient follow-up. CONCLUSIONS: In patients with an old history of non–COVID-19 myocarditis, the risk of recurrent myocarditis after receipt of mRNA COVID-19 vaccination is low, and when it occurs it seems to be self-limiting. Our study will be valuable to clinicians while discussing the risk–benefit ratio of vaccinations in patients with a prior history of myocarditis. Elsevier Inc. 2023-01 2022-07-13 /pmc/articles/PMC9277999/ /pubmed/35842104 http://dx.doi.org/10.1016/j.cardfail.2022.06.011 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Report
Shahid, Rida
Tang, W.H. Wilson
Klein, Allan L.
Kwon, Deborah
Amdani, Shahnawaz
Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title_full Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title_fullStr Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title_full_unstemmed Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title_short Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
title_sort is the mrna covid-19 vaccine safe in patients with a prior history of myocarditis?
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277999/
https://www.ncbi.nlm.nih.gov/pubmed/35842104
http://dx.doi.org/10.1016/j.cardfail.2022.06.011
work_keys_str_mv AT shahidrida isthemrnacovid19vaccinesafeinpatientswithapriorhistoryofmyocarditis
AT tangwhwilson isthemrnacovid19vaccinesafeinpatientswithapriorhistoryofmyocarditis
AT kleinallanl isthemrnacovid19vaccinesafeinpatientswithapriorhistoryofmyocarditis
AT kwondeborah isthemrnacovid19vaccinesafeinpatientswithapriorhistoryofmyocarditis
AT amdanishahnawaz isthemrnacovid19vaccinesafeinpatientswithapriorhistoryofmyocarditis